10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended May 31, 2018

☐   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 333-194055

KANGE CORP.

(Exact name of registrant as specified in its charter)

Nevada	33-1230169
(State or other jurisdiction of incorporation)	(IRS Employer Identification Number)

11724 Ventura Blvd Suite B,Studio City, California 91604

(Address of principal executive offices)

(818) 853-7033

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐ Yes  ☒ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes  ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes   ☒ No

As of May 28, 2021, the Company had 14,553,465 shares of common stock outstanding.

KANGE CORP.

INDEX

		Page
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3.	Quantitative and Qualitative Disclosures about Market Risks	8
Item 4.	Controls and Procedures	8
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	9
Item 1A.	Risk Factors	9
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	9
Item 3.	Defaults Upon Senior Securities	9
Item 4.	Mine Safety Disclosures	9
Item 5.	Other Information	9
Item 6.	Exhibits	10
SIGNATURES		11

2

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Kange Corp.

Index to Financial Statements

	Page
Balance Sheets at May 31, 2018 and November 30, 2017 (unaudited)		F-1
Statements of Operations for the three and six months ended May 31, 2018 and 2017 (unaudited)		F-2
Statement of Changes in Stockholders’ Equity (Deficit) for the six months ended May 31, 2018 and 2017 (unaudited)		F-3
Statements of Cash Flows for the six months ended May 31, 2018 and 2017 (unaudited)		F-4
Notes to Financial Statements (unaudited)		F-5

3

Kange Corp
Balance Sheets
(Unaudited)
	As of			As of
	May 31,			November 30,
	2018			2017
ASSETS
Current Assets
Cash	$	-		$	77
Marketable securities		45,129			81,000
Prepaid expenses		25,019			66,312
Total Current Assets		70,148			147,389
TOTAL ASSETS	$	70,148		$	147,389
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued liabilities	$	10,706		$	5,250
Accrued expenses - related party		3,000			1,000
Due to related parties		-			26,901
Total Current Liabilities		13,706			33,151
Stockholders' Equity
Common stock, $0.001 par value, 750,000,000 shares authorized, 14,553,465 and 14,165,842 shares issued and outstanding, respectively		14,553			14,166
Additional paid-in capital		1,292,474			808,332
Accumulated deficit		(1,250,585	)		(708,260	)
Total Stockholders' Equity		56,442			114,238
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	70,148		$	147,389

The accompanying notes are an integral part of these unaudited financial statements.

F-1

Kange Corp
Statements of Operations (Unaudited)
	Three Months Ended						Six Months Ended
	May 31,						May 31,
	2018			2017			2018			2017
Revenues	$	-		$	-		$	-		$	-
Operating Expenses
General and administrative		4,095			6,571			12,783			14,580
Consulting		20,581			-			41,293			-
Total operating expenses		24,676			6,571			54,076			14,580
Operating loss		(24,676	)		(6,571	)		(54,076	)		(14,580	)
Other expenses
Interest expense		-			(1,627	)		-			(3,254	)
Amortization of debt discount		-			(620	)		-			(2,170	)
Loss on settlement of debt – related party		(452,378	)		-			(452,378	)		-
Unrealized loss on marketable securities		(68,734	)		-			(35,871	)		-
Total other expenses		(521,112	)		(2,247	)		(488,249	)		(5,424	)
Net loss	$	(545,788	)	$	(8,818	)	$	(542,325	)	$	(20,004	)
Basic and diluted loss per common share	$	(0.04	)	$	(0.00	)	$	(0.04	)	$	(0.00	)
Basic and diluted weighted average common shares outstanding		14,536,612			10,570,000			14,352,240			10,570,000

The accompanying notes are an integral part of these unaudited financial statements.

F-2

Kange Corp

Statement of Changes in Stockholders' Equity (Deficit)

(Unaudited)

For the Six Months Ended May 31, 2018
					Additional					Total
	Common Stock				Paid-in		Accumulated			Stockholders’
	Shares		Amount		Capital		Deficit			Equity
Balance - November 30, 2017		14,165,842	$	14,166	$	808,332	$	(708,260	)	$	114,238
Net income for the period		-		-		-		3,463			3,463
Balance - February 28, 2018		14,165,842		14,166		808,332		(704,797	)		117,701
Shares issued for debt settlement		387,623		387		484,142		-			484,529
Net loss for the period		-		-		-		(545,788	)		(545,788	)
Balance - May 31, 2018		14,553,465	$	14,553	$	1,292,474	$	(1,250,585	)	$	56,442

For the Six Months Ended May 31, 2017
					Additional					Total
	Common Stock				Paid-in		Accumulated			Stockholders’
	Shares		Amount		Capital		Deficit			Equity
Balance - November 30, 2016		10,570,000	$	10,570	$	541,253	$	(620,228	)	$	(68,405	)
Net loss for the period		-		-		-		(11,186	)		(11,186	)
Balance - February 28, 2017		10,570,000		10,570		541,253		(631,414	)		(79,591	)
Net loss for the period		-		-		-		(8,818	)		(8,818	)
Balance - May 31, 2017		10,570,000	$	10,570	$	541,253	$	(640,232	)	$	(88,409	)

The accompanying notes are an integral part of these unaudited financial statements.

F-3

Kange Corp
Statements of Cash Flows
(Unaudited)
	Six Months Ended
	May 31,
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(542,325	)	$	(20,004	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount		-			2,170
Unrealized loss on marketable securities		35,871			-
Loss on settlement of debt		452,378			-
Changes in operating assets and liabilities:
Prepaid expenses		41,293			-
Accounts payable and accrued liabilities		5,456			5,082
Accrued expenses to related party		6,000			4,005
Net cash used in operating activities		(1,327	)		(8,747	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from loan from related party		1,250			8,669
Net cash provided by financing activities		1,250			8,669
Net change in cash for the period		(77	)		(78	)
Cash at beginning of period		77			155
Cash at end of period	$	-		$	77
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	-		$	-
NON-CASH INVESTING AND FINANCING ACTIVITIES
Stock issued for debt to related party	$	484,529		$	-

The accompanying notes are an integral part of these unaudited financial statements.

F-4

KANGE CORP.

NOTES TO FINANCIAL STATEMENTS

MAY 31, 2018

(Unaudited)

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

Organization

Kange Corp. ("Kange," the "Company," "we," "us," or "our") was incorporated under the laws of the State of Nevada on August 16, 2013 (Inception). We are a start-up company developing mobile software products, for Apple and Android platforms, starting in Estonia and Europe, which is our initial intended market. Apple is a trademark of Apple Inc., and Android is a trademark of Alphabet Inc. During 2017, we began focusing on the intersection of technology and wholistic technology-based health treatments, we retained an advisor having substantial experience in the technology sector, we retained two former professional athletes to advise us regarding sports health issues and treatments, and we intend to provide services to formulate a treatment model to meet the needs of professional athletes that suffer from PTSD and the early onset of dementia and Alzheimer’s. The Company is currently evaluating operations in the wholistic health industry.

Basis of Presentation

The accompanying unaudited financial statements of the Company are condensed and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended November 30, 2017. The results of operations for the period ended May 31, 2018 are not necessarily indicative of the operating results for the full year.

Fair Value of Financial Instruments

The Company measures its financial assets and liabilities in accordance with generally accepted accounting principles. For certain of our financial instruments, including cash, accounts payable, accrued expenses, and short-term loans the carrying amounts approximate fair value due to their short maturities.

Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company used cash in operating activities of $1,327 for the six months ended May 31, 2018. The Company had an accumulated deficit of $1,250,585 at May 31, 2018. These factors raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate revenues and its ability to continue receiving investment capital and loans from related parties to sustain its current level of operations. The Company is in the process of securing working capital from investors for common stock, convertible notes payable, and/or strategic partnerships. No assurance can be given that the Company will be successful in these efforts.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Net Earnings (Loss) Per Share

In accordance with ASC 260-10, "Earnings per Share," basic net earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted average number of common and dilutive common stock equivalent shares outstanding during the period, which are excluded from the computation if anti-dilutive. There are no dilutive or potentially dilutive securities outstanding during the periods presented.

F-5

Effect of Recent Accounting Pronouncements

The Company reviews new accounting pronouncements as issued. Except as disclosed in Note 2, no new pronouncements had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these financial statements as presented and does not anticipate the need for any future restatement of these financial statements because of the retro-active application of any accounting pronouncements issued subsequent to May 31, 2018 through the date these financial statements were issued.

NOTE 2 – MARKETABLE SECURITIES

We adopted ASU 2016-01 on December 1, 2017, which requires us to measure all equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in earnings. We use quoted market prices to determine the fair value of equity securities with readily determinable fair values.

On November 1, 2017 the Company executed a stock purchase agreement (the “SPA”) with AMJ Global Entertainment, LLC, a related party and holder of 4,803,195 shares of common stock in Patient Access Solutions Inc., a Nevada corporation with ticker symbol “PASO”. Pursuant to the SPA, the Company issued 158,824 shares of common stock in exchange for 1,157,142 shares of Patient Access Solutions Inc.

On November 1, 2017, the Company recorded the shares of Patient Access Solutions Inc. at $81,000. As of May 31, 2018, based quoted market prices, the Company recognized an unrealized loss of $35,871.

The carrying values of our equity securities were included in the following line items in our balance sheets:

Equity securities at November 30, 2017	$	81,000
Addition of equity securities		-
Net unrealized loss recognized during the period related to equity securities still held at the end of the period		(35,871	)
Equity securities at May 31, 2018	$	45,129

NOTE 3 – RELATED PARTY TRANSACTIONS

In support of the Company's efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances are considered temporary in nature and have not been formalized by a promissory note.

On November 1, 2017, the Company entered into a one-year office lease agreement with AMJ Global Entertainment LLC, a related party controlled by the Company’s CEO and director, ending November 2, 2018. The location of the leased office space is 11724 Ventura Blvd Suite B, Studio City, California 91604. The lease states monthly rent due of $1,000. During the six months ended May 31, 2018, the Company accrued $6,000 due to related party. As of May 31, 2018 and November 30, 2017, the Company has accrued lease expense due to related party of $3,000 and $1,000, respectively.

At November 30, 2017, the Company owed $26,901 to AMJ Global Entertainment LLC, a related party controlled by the Company’s CEO and director. The amount is unsecured, non-interest bearing and due on demand. During the six months ended May 31, 2018 and 2017, the Company received proceeds of $1,250 and $8,669, respectively, from the related party. On March 5, 2018, the Company settled the loans totaling $28,151 in addition to $4,000 accrued related party payables by the issuance of 387,623 shares of common stock valued at $484,529. As a result, the Company recorded a loss on settlement of debt of $452,378.

NOTE 4 – COMMON STOCK

Common Stock

On November 27, 2017, the Company increased its authorized shares of common stock from 75,000,000 to 750,000,000, par value $0.001 per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.

F-6

During the year ended November 30, 2017, the Company issued a total of 155,000 shares of common stock to five separate consultants pursuant to advisory board agreements. Three advisory board agreements were made effective on May 25, 2017 with terms of 15,000 shares each to be issued for one year of services to be rendered. Two advisory board agreements were made effective on October 1, 2017 with terms of 30,000 shares each to be issued for one year of services. The Company valued the advisory agreement shares based on the closing stock price of the Company on the date of the executed agreement (the grant date), which resulted in a total combined value of $124,000 initially recorded as prepaid expense to be amortized ratably over the contract term. During the six months ended May 31, 2018, the Company recorded consulting expense in the amount of $41,293, resulting in the remaining balance of prepaid expense, the uncompleted portion of the contract, of $25,019 and $66,312 at May 31, 2018 and November 30, 2017, respectively.

On March 5, 2018, the Company issued 387,623 shares of common stock valued at $484,529 to settled debt of $32,151 owed to a related party (Note 3).

There were 14,553,465 and 14,165,842 shares of common stock issued and outstanding as of May 31, 2018 and November 30, 2017, respectively.

NOTE 5 – SUBSEQUENT EVENTS

On January 13, 2020, the transaction related to stock purchase agreement with AMJ Global Entertainment, LLC, a related party and holder of 4,803,195 shares of common stock in Patient Access Solutions Inc. (see Note 2), was rescinded, and the Company will return 1,157,142 shares of Patient Access Solutions Inc. back to AMJ Global Entertainment, LLC in exchange for 157,142 shares of the Company.

The Company has evaluated events occurring subsequent to the balance sheet date through the date these financial statements were issued, and determined there are no additional events requiring disclosure.

F-7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Rule 175 of the Securities Act of 1933, as amended, and Rule 3b-6 of the Securities Act of 1934, as amended, that involve substantial risks and uncertainties. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. Words such as “anticipate,” “expects,” “intends,” “plans,” “believes,” “seeks” and “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Form 10-Q. Investors should carefully consider all of such risks before making an investment decision with respect to the Company’s stock. The following discussion and analysis should be read in conjunction with our financial statements and summary of selected financial data for Kange Corp. Such discussion represents only the best present assessment from our Management.

Company Overview

Kange Corp., a Nevada corporation (the “Company,” “Kange,” “we,” and “us”), is an early-stage company that was incorporated in Nevada on August 16, 2013.

The Company has historically focused on developing and marketing software product as mobile applications for end users of iPhone and iPad from Apple, Inc., and mobile phones using the Android platform, and since 2017, has been focusing on the intersection of technology and wholistic technology-based health treatments, and with the intention to provide services to formulate a treatment model to meet the needs of professional athletes that suffer from PTSD and the early onset of dementia and Alzheimer’s. The Company is currently evaluating operations in the wholistic health industry.

On November 9, 2015, AMJ Global, LLC ("AMJ Global"), a company beneficially owned by Dr. Arthur Malone, Jr., the Company's chief executive officer and director, assigned the rights of AMJ Global pursuant to its agreements with Blabeey, Inc. ("Blabeey"), a mobile App designer. The irrevocable assignment, transferred and conveyed in its entirety to the Company in a common control transaction, all of AMJ Global's rights and obligations that are stipulated and set forth in every and all agreements between AMJ Global and Blabeey, including, but not limited to, the agreement between AMJ Global and Blabeey dated October 26, 2015. Blabeey's web site is www.blabeey.com, which is not incorporated in this filing. The Company issued 5,000,000 shares of common stock to AMJ Global for the assignment. The Company valued those shares at $471,672, the historical asset costs of Blabeey. Since the Company’s transaction with AMJ Global was between entities under common control, the amount of the historical cost of the assets, $471,672, was recorded as an expense in 2015 as there was no fixed and determinable future value, and the expense was recorded as a loss on the acquisition of contractual rights. Subsequently, the Company began working with Blabeey on developing technology for social media regarding Autism, PTSD and other neurological issues, and the Company is still consulting with Blabeey regarding software development opportunities in connection with the wholistic health industry.

In May of 2017, the Company retained Bruce Weitzberg to serve on the Company’s Board of Advisors and advise the Company regarding the intersection of technology and wholistic health care treatment and healthy living. Mr. Weitzberg is the CEO of Patient Access Solutions Inc., a Nevada corporation with ticker symbol “PASO” (“PASO”). PASO is a provider of healthcare and financial processing solutions for the healthcare and dental industries, and it has also opened a new center for the treatment of individuals with autism spectrum disorder and other biomedical conditions.

Subsequently, the Company retained James Lantiegne, a professional magician and former COO and CFO of a national software company, to serve on the Company’s Board of Advisors and provide the Company advice on the intersection of technology and health. In October of 2017, the Company retained Benny Malone, former NFL running back for the Miami Dolphins and Washington Redskins, and Eric Metcalf, former NFL running back, wide receiver and three-time Pro-Bowl selection, to serve on the Company’s Board of Advisors and advise the Company regarding sports health issues and treatments.

On November 1, 2017, the Company executed a stock purchase agreement (the “SPA”) with AMJ Global Entertainment, LLC, another related party company controlled by our CEO and director, Dr. Arthur Malone, Jr., to purchase 1,157,142 shares of Patient Access Solutions Inc., a Nevada corporation with ticker symbol “PASO” (“PASO”), in consideration of the issuance of 158,824 shares of our common stock. PASO is a provider of healthcare and financial processing solutions for the healthcare and dental industries, and it has also opened a new center for the treatment of individuals with autism spectrum disorder and other biomedical conditions. The Company is currently advising PASO on formulating a treatment model to meet the needs of professional athletes that suffer from PTSD and the early onset of dementia and Alzheimer’s. The Company is currently evaluating wholistic technology-based healthcare treatments, and is evaluating potential additional operations in the wholistic health industry. On January 13, 2020, the transaction was rescinded, and the Company will return 1,157,142 shares of Patient Access Solutions Inc. back to AMJ Global Entertainment, LLC in exchange for 157,142 shares of the Company.

4

We have had limited operations and have been issued a "going concern" opinion by our auditor, based upon our reliance on related party loans and the sale of our common stock as the sole sources of funds for our operations for the near future.

Reports to Security Holders

The Company is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, and is a “voluntary filer.” As a voluntary filer, the Company intends to furnish its stockholders with annual reports containing consolidated financial statements audited by its independent registered public accounting firm and to make available quarterly reports containing unaudited consolidated financial statements for each of the first three quarters of each year, but is not obligated to do so. The Company files Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K with the Securities and Exchange Commission. The Company may also file additional documents with the Commission if those documents become necessary in the course of its operations.

Available Information

All reports of the Company filed with the SEC are available free of charge through the SEC’s website at www.sec.gov. In addition, the public may read and copy materials filed by the Company at the SEC’s Public Reference Room located at 100 F Street, N.E., Washington, D.C. 20549. The public may also obtain additional information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330.

Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and notes thereto for the three and six months ended May 31, 2018 and 2017, and related management discussion herein.

Our financial statements are stated in U.S. Dollars and are prepared in accordance with generally accepted accounting principles of the United States (“GAAP”).

Going Concern Qualification

Several conditions and events cast substantial doubt about the Company’s ability to continue as a going concern. The Company has incurred cumulative net losses of $1,250,585 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through debt or future issuances of capital stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern.

For the Three Months Ended May 31, 2018 and 2017:

Our operating results for the three months ended May 31, 2018 and 2017, and the changes between those periods for the respective items, are summarized as follows:

	Three Months Ended
	May 31,						Change
	2018			2017			Amount
Operating loss	$	(24,676	)	$	(6,571	)	$	(18,105	)
Other expense		(521,112	)		(2,247	)		(518,865	)
Net loss	$	(545,788	)	$	(8,818	)	$	(536,970	)

During the three months ending May 31, 2018 the Company had an operating loss of $24,676, recognized a loss on debt settlement of $452,378 due to shares issuance for debt to related party, and recognized an unrealized loss on marketable securities of $68,734 due to revaluation of marketable securities. For the same period in the prior fiscal year, the Company recorded an operating loss of $6,571, interest expense of $1,627, and amortization of debt discount of $620. The increase in operating loss during the three months ended May 31, 2018, is primarily due to consulting fees of $20,581.

5

For the Six Months Ended May 31, 2018 and 2017:

Our operating results for the six months ended May 31, 2018 and 2017, and the changes between those periods for the respective items, are summarized as follows:

	Six Months Ended
	May 31,						Change
	2018			2017			Amount
Operating loss	$	(54,076	)	$	(14,580	)	$	(39,496	)
Other expense		(488,249	)		(5,424	)		(482,825	)
Net loss	$	(542,325	)	$	(20,004	)	$	(522,321	)

Revenues

We did not earn any revenues during the six months ending May 31, 2018 or 2017.

Operating Loss

Our loss from operations increased to $54,076 during the six months ending May 31, 2018, from an operating loss of $14,580 in the comparative period ending May 31, 2017. The following table presents operating expenses for the six-month periods ending May 31, 2018 and 2017:

	Six Months Ended
	May 31,				Change
	2018		2017		Amount			Percentage
Consulting Fees	$	41,293	$	-	$	41,293			-
General and administrative expenses		12,783		14,580		(1,797	)	(12		%)
Total Operating Expenses	$	54,076	$	14,580	$	39,496			271	%

The Company recorded $41,293 in consulting fees during the six months ended May 31, 2018, as compared to $0 for the same period in the prior fiscal year, due to signed advisory board agreements. We realized a decrease of $1,797 in general and administrative expenses during the six months ended May 31, 2018, as compared to the same period in the prior fiscal year.

Other Income (Expense)

The following table presents other income and expenses for the six months ended May 31, 2018 and 2017:

	Six Months Ended
	May 31,
	2018		2017
Loss on settlement of debt	$	452,378	$	-
Unrealized Loss on marketable securities		35,871		-
Interest expense		-		3,254
Amortization of debt discount		-		2,170
Total expense	$	488,249	$	5,424

During the six months ending May 31, 2018 the Company recognized loss on debt settlement of $452,378 due to shares issued for debt to related party. During the six months ending May 31, 2018 the Company recognized an unrealized loss on marketable securities of $35,871 due to revaluation of marketable securities. For the same period in the prior fiscal year, the Company recorded interest expense of $3,254, and amortization of debt discount of $2,170.

6

Net Loss

The Company incurred a $542,325 net loss during the six months ended May 31, 2018, compared to net loss of $20,004 in the same period in the prior fiscal year. This is due to loss on settlement of debt, and the net effect of the consulting fees and unrealized loss on marketable securities recognized during the 2018 period.

Liquidity and Capital Resources

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

Working Capital

The following table presents our working capital position as of May 31, 2018 and November 30, 2017:

	As of		As of
	May 31,		November 30,		Change
	2018		2017		Amount			Percentage
Cash	$	-	$	77	$	(77	)		-
Marketable securities		45,129		81,000		(35,871	)	(44%)
Prepaid expenses		25,019		66,312		(41,293	)	(62%)
Current Assets		70,148		147,389		(77,241	)	(52%)
Current Liabilities		13,706		33,151		(19,445	)	(59%)
Working Capital	$	56,442	$	114,238	$	(57,796	)	(51%)

The change in working capital during the six months ended May 31, 2018, was primarily due to a decrease in current assets of $77,241 and a decrease in current liabilities of $19,445. Current assets decreased primarily due to revaluation of investment in marketable securities and amortization of prepaid consulting expense. Current liabilities decreased due to the net effect of an increase in accounts payable and accrued liabilities of $5,456, debt settlement to related party of $32,151 and increase in accrued expenses due to related party of $6,000. Cash reduced as of May 31, 2018, by $77 to $0.

Cash Flow

We fund our operations with cash received from advances from officers and related parties and issuances of equity.

The following tables presents our cash flow for the six months ended May 31, 2018 and 2017:

	Six Months Ended
	May 31,
	2018			2017
Cash (used in) operating activities	$	(1,327	)	$	(8,747	)
Cash provided by financing activities		1,250			8,669
Net change in cash for the period	$	(77	)	$	(78	)

Cash Flows from Operating Activities

We did not generate positive cash flows from operating activities for the six months ended May 31, 2018 or 2017.

For the six months ended May 31, 2018, net cash flows used in operating activities consisted of a net loss of $542,325, reduced by unrealized loss on marketable securities of $35,871, loss on settlement of debt of $452,378 and by a net increase in change of operating assets and liabilities of $52,749.

7

For the six months ended May 31, 2017, net cash flows used in operating activities consisted of a net loss of $20,004, reduced by amortization of debt discount of $2,170 and net change in operating assets and liabilities of $9,087.

Cash Flows from Investing Activities

For the six months ended May 31, 2018 and 2017, no cashflows were provided by or used in investing activities.

Cash Flows from Financing Activities

For the six months ended May 31, 2018 and 2017, we received $1,250 and $8,669, respectively, in advances from related parties, which used to fund operations and business activities.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

The Securities and Exchange Commission defines the term “disclosure controls and procedures” to mean the company’s controls and other procedures of an issuer that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company maintains such a simple system of controls and procedures in an effort to ensure that all information which it is required to disclose in the reports it files under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified under the SEC’s rules and forms and that information required to be disclosed is accumulated and communicated to principal executive and principal financial officers to allow timely decisions regarding disclosure.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were not effective to provide reasonable assurance of achieving the objectives of timely alerting them to material information required to be included in our periodic SEC reports and of ensuring that such information is recorded, processed, summarized and reported with the time periods specified. Our chief executive officer and chief financial officer also concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report to provide reasonable assurance of the achievement of these objectives.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act that occurred during the quarter ended May 31, 2018, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

8

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The Company is not a party to any significant pending legal proceedings other than as disclosed below, and no other such proceedings are known to be contemplated. No director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than 5.0% of the securities of the Company, or any associate of any such director, officer or security holder is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.

ITEM 1A. RISK FACTORS.

Not applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

None.

ITEM 5. OTHER INFORMATION.

None.

9

ITEM 6. EXHIBITS.

Exhibit	Description
3.1	Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1, filed on February 21, 2014)
3.2	Bylaws (incorporated by reference to our Registration Statement on Form S-1, filed on February 21, 2014)
10.1	Assignment of Rights Agreement between the Company and AMJ Global (incorporated by reference to our Current Report on Form 8-K filed on November 12, 2015)
31.1*	Certification of CEO required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63
101.INS**	XBRL Instance Document
101.SCH**	XBRL Taxonomy Extension Schema Document
101.CAL**	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**	XBRL Taxonomy Extension Label Linkbase Document
101.PRE**	XBRL Taxonomy Extension Presentation Linkbase Document

____________

* Filed herewith.

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

10

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	KANGE CORP.
Date: June 1, 2021	By:	/s/ Dr. Arthur Malone, Jr.
		Dr. Arthur Malone, Jr.
		Chief Executive Officer, Chief Financial Officer & Director

11

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Dr. Arthur Malone, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Kange Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 1, 2021	By:	/s/ Dr. Arthur Malone, Jr.
		Dr. Arthur Malone, Jr.
		Chief Executive Officer and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Dr. Arthur Malone, Jr., Chief Executive Officer and Chief Financial Officer of Kange Corp. (the "Company"), certify, pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Quarterly Report on Form 10-Q of the Company for the period ended May 31, 2018 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 1, 2021	By:	/s/ Dr. Arthur Malone, Jr.
		Dr. Arthur Malone, Jr.
		Chief Executive Officer and Chief Financial Officer

XML

Cover - shares	6 Months Ended
	May 31, 2018	May 28, 2021
Cover [Abstract]
Entity Registrant Name	KANGE CORP.
Entity Central Index Key	0001593773
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--11-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	No
Document Period End Date	May 31, 2018
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		14,553,465
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-194055
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	33-1230169
Entity Address Address Line 1	11724 Ventura Blvd Suite B
Entity Address City Or Town	Studio City
Entity Address State Or Province	CA
Entity Address Postal Zip Code	91604
City Area Code	818
Local Phone Number	853-7033
Entity Interactive Data Current	Yes

XML

Balance Sheets - USD ($)	May 31, 2018	Nov. 30, 2017
Current Assets
Cash	$ 0	$ 77
Marketable securities	45,129	81,000
Prepaid expenses	25,019	66,312
Total Current Assets	70,148	147,389
TOTAL ASSETS	70,148	147,389
Current Liabilities
Accounts payable and accrued liabilities	10,706	5,250
Accrued expenses - related party	3,000	1,000
Due to related parties	0	26,901
Total Current Liabilities	13,706	33,151
Stockholders' Equity
Common stock, $0.001 par value, 750,000,000 shares authorized, 14,553,465 and 14,165,842 shares issued and outstanding, respectively	14,553	14,166
Additional paid-in capital	1,292,474	808,332
Accumulated deficit	(1,250,585)	(708,260)
Total Stockholders' Deficit	56,442	114,238
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 70,148	$ 147,389

XML

Balance Sheets (Parenthetical) - $ / shares	May 31, 2018	Nov. 30, 2017
Stockholders' deficit
Common stock, Par value	$ 0.001	$ 0.001
Common stock, Authorized	750,000,000	750,000,000
Common Stock, Shares Issued	14,553,465	14,165,842
Common stock, Shares Outstanding	14,553,465	14,165,842

XML

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	May 31, 2018	May 31, 2017	May 31, 2018	May 31, 2017
Statements of Operations (Unaudited)
Revenues	$ 0	$ 0	$ 0	$ 0
Operating Expenses
General and administrative	4,095	6,571	12,783	14,580
Consulting	20,581	0	41,293	0
Total operating expenses	24,676	6,571	54,076	14,580
Operating loss	(24,676)	(6,571)	(54,076)	(14,580)
Other expenses
Interest expense	0	(1,627)	0	(3,254)
Amortization of debt discount	0	(620)	0	(2,170)
Loss on settlement of debt - related party	(452,378)	0	(452,378)	0
Unrealized loss on marketable securities	(68,734)	0	(35,871)	0
Total other expenses	(521,112)	(2,247)	(488,249)	(5,424)
Net loss	$ (545,788)	$ (8,818)	$ (542,325)	$ (20,004)
Basic and diluted loss per common share	$ (0.04)	$ (0.00)	$ (0.04)	$ (0.00)
Basic and diluted weighted average common shares outstanding	14,536,612	10,570,000	14,352,240	10,570,000

XML

Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Nov. 30, 2016		10,570,000
Balance, amount at Nov. 30, 2016	$ (68,405)	$ 10,570	$ 541,253	$ (620,228)
Net loss for the period	(11,186)	$ 0	0	(11,186)
Balance, shares at Feb. 28, 2017		10,570,000
Balance, amount at Feb. 28, 2017	(79,591)	$ 10,570	541,253	(631,414)
Balance, shares at Nov. 30, 2016		10,570,000
Balance, amount at Nov. 30, 2016	(68,405)	$ 10,570	541,253	(620,228)
Net loss for the period	(20,004)
Balance, shares at May. 31, 2017		10,570,000
Balance, amount at May. 31, 2017	(88,409)	$ 10,570	541,253	(640,232)
Balance, shares at Feb. 28, 2017		10,570,000
Balance, amount at Feb. 28, 2017	(79,591)	$ 10,570	541,253	(631,414)
Net loss for the period	(8,818)	$ 0	0	(8,818)
Balance, shares at May. 31, 2017		10,570,000
Balance, amount at May. 31, 2017	(88,409)	$ 10,570	541,253	(640,232)
Balance, shares at Nov. 30, 2017		14,165,842
Balance, amount at Nov. 30, 2017	114,238	$ 14,166	808,332	(708,260)
Net loss for the period	3,463	$ 0	0	3,463
Balance, shares at Feb. 28, 2018		14,165,842
Balance, amount at Feb. 28, 2018	117,701	$ 14,166	808,332	(704,797)
Balance, shares at Nov. 30, 2017		14,165,842
Balance, amount at Nov. 30, 2017	114,238	$ 14,166	808,332	(708,260)
Net loss for the period	(542,325)
Balance, shares at May. 31, 2018		14,553,465
Balance, amount at May. 31, 2018	56,442	$ 14,553	1,292,474	(1,250,585)
Balance, shares at Feb. 28, 2018		14,165,842
Balance, amount at Feb. 28, 2018	117,701	$ 14,166	808,332	(704,797)
Net loss for the period	(545,788)	$ 0	0	(545,788)
Shares issued for debt settlement, shares		387,623
Shares issued for debt settlement, amount	484,529	$ 387	484,142	0
Balance, shares at May. 31, 2018		14,553,465
Balance, amount at May. 31, 2018	$ 56,442	$ 14,553	$ 1,292,474	$ (1,250,585)

XML

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	May 31, 2018	May 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (542,325)	$ (20,004)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	0	2,170
Unrealized loss on marketable securities	35,871	0
Loss on settlement of debt	452,378	0
Changes in operating assets and liabilities:
Prepaid expenses	41,293	0
Accounts payable and accrued liabilities	5,456	5,082
Accrued expenses to related party	6,000	4,005
Net cash used in operating activities	(1,327)	(8,747)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from loan from related party	1,250	8,669
Net cash provided by financing activities	1,250	8,669
Net change in cash for the period	(77)	(78)
Cash at beginning of period	77	155
Cash at end of period	0	77
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	0	0
Cash paid for interest	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES
Stock issued for debt to related party	$ 484,529	$ 0

XML

ORGANIZATION AND NATURE OF BUSINESS

6 Months Ended

May 31, 2018

ORGANIZATION AND NATURE OF BUSINESS

NOTE 1 - ORGANIZATION AND NATURE OF BUSINESS

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

Organization

Kange Corp. ("Kange," the "Company," "we," "us," or "our") was incorporated under the laws of the State of Nevada on August 16, 2013 (Inception). We are a start-up company developing mobile software products, for Apple and Android platforms, starting in Estonia and Europe, which is our initial intended market. Apple is a trademark of Apple Inc., and Android is a trademark of Alphabet Inc. During 2017, we began focusing on the intersection of technology and wholistic technology-based health treatments, we retained an advisor having substantial experience in the technology sector, we retained two former professional athletes to advise us regarding sports health issues and treatments, and we intend to provide services to formulate a treatment model to meet the needs of professional athletes that suffer from PTSD and the early onset of dementia and Alzheimer’s. The Company is currently evaluating operations in the wholistic health industry.

Basis of Presentation

The accompanying unaudited financial statements of the Company are condensed and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended November 30, 2017. The results of operations for the period ended May 31, 2018 are not necessarily indicative of the operating results for the full year.

Fair Value of Financial Instruments

The Company measures its financial assets and liabilities in accordance with generally accepted accounting principles. For certain of our financial instruments, including cash, accounts payable, accrued expenses, and short-term loans the carrying amounts approximate fair value due to their short maturities.

Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company used cash in operating activities of $1,327 for the six months ended May 31, 2018. The Company had an accumulated deficit of $1,250,585 at May 31, 2018. These factors raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate revenues and its ability to continue receiving investment capital and loans from related parties to sustain its current level of operations. The Company is in the process of securing working capital from investors for common stock, convertible notes payable, and/or strategic partnerships. No assurance can be given that the Company will be successful in these efforts.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Net Earnings (Loss) Per Share

In accordance with ASC 260-10, "Earnings per Share," basic net earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted average number of common and dilutive common stock equivalent shares outstanding during the period, which are excluded from the computation if anti-dilutive. There are no dilutive or potentially dilutive securities outstanding during the periods presented.

Effect of Recent Accounting Pronouncements

The Company reviews new accounting pronouncements as issued. Except as disclosed in Note 2, no new pronouncements had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these financial statements as presented and does not anticipate the need for any future restatement of these financial statements because of the retro-active application of any accounting pronouncements issued subsequent to May 31, 2018 through the date these financial statements were issued.

XML

MARKETABLE SECURITIES

6 Months Ended

May 31, 2018

MARKETABLE SECURITIES

NOTE 2 - MARKETABLE SECURITIES

NOTE 2 – MARKETABLE SECURITIES

We adopted ASU 2016-01 on December 1, 2017, which requires us to measure all equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in earnings. We use quoted market prices to determine the fair value of equity securities with readily determinable fair values.

On November 1, 2017 the Company executed a stock purchase agreement (the “SPA”) with AMJ Global Entertainment, LLC, a related party and holder of 4,803,195 shares of common stock in Patient Access Solutions Inc., a Nevada corporation with ticker symbol “PASO”. Pursuant to the SPA, the Company issued 158,824 shares of common stock in exchange for 1,157,142 shares of Patient Access Solutions Inc.

On November 1, 2017, the Company recorded the shares of Patient Access Solutions Inc. at $81,000. As of May 31, 2018, based quoted market prices, the Company recognized an unrealized loss of $35,871.

The carrying values of our equity securities were included in the following line items in our balance sheets:

Equity securities at November 30, 2017	$	81,000
Addition of equity securities		-
Net unrealized loss recognized during the period related to equity securities still held at the end of the period		(35,871	)
Equity securities at May 31, 2018	$	45,129

XML

RELATED PARTY TRANSACTIONS

6 Months Ended

May 31, 2018

RELATED PARTY TRANSACTIONS

NOTE 3 - RELATED PARTY TRANSACTIONS

NOTE 3 – RELATED PARTY TRANSACTIONS

In support of the Company's efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales of its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders. Amounts represent advances or amounts paid in satisfaction of liabilities. The advances are considered temporary in nature and have not been formalized by a promissory note.

On November 1, 2017, the Company entered into a one-year office lease agreement with AMJ Global Entertainment LLC, a related party controlled by the Company’s CEO and director, ending November 2, 2018. The location of the leased office space is 11724 Ventura Blvd Suite B, Studio City, California 91604. The lease states monthly rent due of $1,000. During the six months ended May 31, 2018, the Company accrued $6,000 due to related party. As of May 31, 2018 and November 30, 2017, the Company has accrued lease expense due to related party of $3,000 and $1,000, respectively.

At November 30, 2017, the Company owed $26,901 to AMJ Global Entertainment LLC, a related party controlled by the Company’s CEO and director. The amount is unsecured, non-interest bearing and due on demand. During the six months ended May 31, 2018 and 2017, the Company received proceeds of $1,250 and $8,669, respectively, from the related party. On March 5, 2018, the Company settled the loans totaling $28,151 in addition to $4,000 accrued related party payables by the issuance of 387,623 shares of common stock valued at $484,529. As a result, the Company recorded a loss on settlement of debt of $452,378.

XML

COMMON STOCK

6 Months Ended

May 31, 2018

COMMON STOCK

NOTE 4 - COMMON STOCK

NOTE 4 – COMMON STOCK

Common Stock

On November 27, 2017, the Company increased its authorized shares of common stock from 75,000,000 to 750,000,000, par value $0.001 per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.

During the year ended November 30, 2017, the Company issued a total of 155,000 shares of common stock to five separate consultants pursuant to advisory board agreements. Three advisory board agreements were made effective on May 25, 2017 with terms of 15,000 shares each to be issued for one year of services to be rendered. Two advisory board agreements were made effective on October 1, 2017 with terms of 30,000 shares each to be issued for one year of services. The Company valued the advisory agreement shares based on the closing stock price of the Company on the date of the executed agreement (the grant date), which resulted in a total combined value of $124,000 initially recorded as prepaid expense to be amortized ratably over the contract term. During the six months ended May 31, 2018, the Company recorded consulting expense in the amount of $41,293, resulting in the remaining balance of prepaid expense, the uncompleted portion of the contract, of $25,019 and $66,312 at May 31, 2018 and November 30, 2017, respectively.

On March 5, 2018, the Company issued 387,623 shares of common stock valued at $484,529 to settled debt of $32,151 owed to a related party (Note 3).

There were 14,553,465 and 14,165,842 shares of common stock issued and outstanding as of May 31, 2018 and November 30, 2017, respectively.

XML

SUBSEQUENT EVENTS

6 Months Ended

May 31, 2018

SUBSEQUENT EVENTS

NOTE 5 - SUBSEQUENT EVENTS

NOTE 5 – SUBSEQUENT EVENTS

On January 13, 2020, the transaction related to stock purchase agreement with AMJ Global Entertainment, LLC, a related party and holder of 4,803,195 shares of common stock in Patient Access Solutions Inc. (see Note 2), was rescinded, and the Company will return 1,157,142 shares of Patient Access Solutions Inc. back to AMJ Global Entertainment, LLC in exchange for 157,142 shares of the Company.

The Company has evaluated events occurring subsequent to the balance sheet date through the date these financial statements were issued, and determined there are no additional events requiring disclosure.

XML

ORGANIZATION AND NATURE OF BUSINESS (Policies)

6 Months Ended

May 31, 2018

ORGANIZATION AND NATURE OF BUSINESS

Organization

Kange Corp. ("Kange," the "Company," "we," "us," or "our") was incorporated under the laws of the State of Nevada on August 16, 2013 (Inception). We are a start-up company developing mobile software products, for Apple and Android platforms, starting in Estonia and Europe, which is our initial intended market. Apple is a trademark of Apple Inc., and Android is a trademark of Alphabet Inc. During 2017, we began focusing on the intersection of technology and wholistic technology-based health treatments, we retained an advisor having substantial experience in the technology sector, we retained two former professional athletes to advise us regarding sports health issues and treatments, and we intend to provide services to formulate a treatment model to meet the needs of professional athletes that suffer from PTSD and the early onset of dementia and Alzheimer’s. The Company is currently evaluating operations in the wholistic health industry.

Basis of Presentation

The accompanying unaudited financial statements of the Company are condensed and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended November 30, 2017. The results of operations for the period ended May 31, 2018 are not necessarily indicative of the operating results for the full year.

Fair Value of Financial Instruments

The Company measures its financial assets and liabilities in accordance with generally accepted accounting principles. For certain of our financial instruments, including cash, accounts payable, accrued expenses, and short-term loans the carrying amounts approximate fair value due to their short maturities.

Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company used cash in operating activities of $1,327 for the six months ended May 31, 2018. The Company had an accumulated deficit of $1,250,585 at May 31, 2018. These factors raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate revenues and its ability to continue receiving investment capital and loans from related parties to sustain its current level of operations. The Company is in the process of securing working capital from investors for common stock, convertible notes payable, and/or strategic partnerships. No assurance can be given that the Company will be successful in these efforts.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Net Earnings (Loss) Per Share

In accordance with ASC 260-10, "Earnings per Share," basic net earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed using the weighted average number of common and dilutive common stock equivalent shares outstanding during the period, which are excluded from the computation if anti-dilutive. There are no dilutive or potentially dilutive securities outstanding during the periods presented.

Effect of Recent Accounting Pronouncements

The Company reviews new accounting pronouncements as issued. Except as disclosed in Note 2, no new pronouncements had any material effect on these financial statements. The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these financial statements as presented and does not anticipate the need for any future restatement of these financial statements because of the retro-active application of any accounting pronouncements issued subsequent to May 31, 2018 through the date these financial statements were issued.

XML

MARKETABLE SECURITIES (Tables)

6 Months Ended

May 31, 2018

MARKETABLE SECURITIES

Schedule of value of equity securities

Equity securities at November 30, 2017	$	81,000
Addition of equity securities		-
Net unrealized loss recognized during the period related to equity securities still held at the end of the period		(35,871	)
Equity securities at May 31, 2018	$	45,129

XML

ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - USD ($)	6 Months Ended
	May 31, 2018	May 31, 2017	Nov. 30, 2017
ORGANIZATION AND NATURE OF BUSINESS
Net cash used in operating activities	$ (1,327)	$ (8,747)
Accumulated deficit	$ (1,250,585)		$ (708,260)

XML

MARKETABLE SEC (Details)	6 Months Ended
	May 31, 2018 USD ($)
MARKETABLE SECURITIES
Equity securities at November 30, 2017	$ 81,000
Net unrealized loss recognized during the period related to equity securities still held at the end of the period	(35,871)
Equity securities at February 28, 2018	$ 45,129

XML

MARKETABLE SECURITIES (Details Narrative) - USD ($)		6 Months Ended
	Jan. 13, 2020	May 31, 2018	Nov. 30, 2017	Nov. 01, 2017
Exchange Common Stock Value				$ 81,000
Unrealized gain on investment		$ (35,871)
Common stock, shares issued		14,553,465	14,165,842
Patient Access Solutions Inc [Member]
Common stock, shares issued				158,824
Common stock, shares returned in exchange during period				1,157,142
Amj Global Entertainment LLc [Member]
Common stock, shares rescinded during period	4,803,195

XML

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)		6 Months Ended
	Mar. 05, 2018	May 31, 2018	May 31, 2017	Nov. 30, 2017
Due to related party		$ 0		$ 26,901
Accrued expenses - related party		3,000		1,000
Amj Global [Member]
Due to related party		3,000		$ 1,000
Settlement of loan amount	$ 28,151
Monthly rent of lease		1,000
Accrued expenses - related party	$ 4,000	6,000
Proceeds from the related party		1,250	$ 8,669
Common Stock, Shares Issued During Period, Shares	387,623
Common Stock, Shares Issued During Period, Value	$ 484,529
Loss on settlement of debt		$ 452,378

XML

COMMON STOCK (Details Narrative) - USD ($)		1 Months Ended	6 Months Ended
	Mar. 05, 2018	Nov. 27, 2017	May 31, 2018	Nov. 30, 2017	Oct. 01, 2017	May 25, 2017
Stock Authorized During Period, Shares, Period Increase		750,000,000
Common stock, Par value			$ 0.001	$ 0.001
Common Stock, Shares Issued			14,553,465	14,165,842
Common stock, Shares Outstanding			14,553,465	14,165,842
Consulting expenses			$ 41,293
Prepaid expense			$ 25,019	$ 66,312
Service Agreements [Member]
Common Stock, Shares Issued				155,000
Common stock, shares to be issued					30,000	15,000
Combined shares issued value				$ 124,000
Amj Global [Member]
Settlement of loan amount	$ 32,151
Common Stock, Shares Issued During Period, Shares	387,623
Common Stock, Shares Issued During Period, Value	$ 484,529

XML

SUBSEQUENT EVENTS (Details Narrative)	Jan. 13, 2020 shares
Amj Global Entertainment LLc [Member]
Common stock, shares rescinded during period	4,803,195
Subsequent Event [Member]
Common stock, shares rescinded during period	4,803,195
Common stock, shares returned	1,157,142
Subsequent Event [Member] | Amj Global Entertainment LLc [Member]
Common stock, shares returned in exchange during period	157,142